Vedant Fashions Limited has announced a comprehensive schedule for its Q3FY26 financial results disclosure, including a board meeting on February 12, 2026, followed by an investor conference call on February 13, 2026. The company has structured these events to ensure thorough review and transparent communication of its quarterly performance.

Board Meeting and Results Approval

The board of directors will convene on Thursday, February 12, 2026, with a comprehensive agenda focused on financial performance evaluation. The primary objective involves considering and approving unaudited financial results for the quarter and nine-month period ended December 31, 2025.

Investor Conference Call Details

Following the board meeting, Vedant Fashions Limited has scheduled an investor and analyst conference call on Friday, February 13, 2026, at 3:30 PM IST. The conference call will discuss the company's Q3FY26 results and performance outlook, subject to the approval and announcement of financial results by the board.

Regulatory Compliance and Communication

The announcement was made in strict adherence to regulatory requirements under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Vedant Fashions Limited communicated both the board meeting schedule and conference call details to the National Stock Exchange of India Limited and BSE Limited.

The company formally notified both exchanges about the upcoming events, fulfilling requirements under the Listing Regulations and demonstrating commitment to maintaining proper disclosure standards. The conference call details and registration information will also be made available on the company's website at www.vedantfashions.com .

Financial Review and Investor Engagement

The board meeting will encompass a thorough evaluation of the company's financial performance during the specified period. Directors will review unaudited financial results alongside the auditor's limited review report, providing comprehensive oversight of the company's financial position for both the individual quarter and cumulative nine-month period ended December 31, 2025.

The subsequent investor conference call represents the company's commitment to transparent stakeholder communication, allowing analysts and institutional investors to engage directly with management regarding the quarterly performance and future outlook.

Vedant Fashions Limited has resolved a regulatory compliance issue with the Legal Metrology Department by paying a compounding fee of ₹50,000.00. The company disclosed this development to stock exchanges on January 12, 2026, under Regulation 30 of the SEBI Listing Regulations.

Regulatory Notice and Violation Details

The company received initial communication from the Deputy Controller (Enforcement) Legal Metrology Department, Anantnag, Pulwama, Jammu & Kashmir through a memo dated October 10, 2025, followed by a show cause notice on November 15, 2025. The notices cited violations under Rule 9 of the Legal Metrology Packaged Commodity Rules, 2011.

Company Response and Resolution Process

Vedant Fashions took proactive steps to address the regulatory concerns. On December 9, 2025, the company submitted a formal request letter seeking compounding of the alleged offense. The Legal Metrology Department responded positively to this request.

The resolution timeline proceeded as follows:

Financial Impact and Compounding Fee

The Legal Metrology Department issued a notice on December 31, 2025, directing the company to deposit ₹50,000.00 as compounding fee. Vedant Fashions completed the payment on January 9, 2026, and formally notified the authority through a letter dated January 12, 2026.

Regulatory Compliance Disclosure

As per SEBI Listing Regulations, Vedant Fashions provided comprehensive details of the regulatory action to both NSE and BSE. The company confirmed that apart from the compounding fee amount, there is no other impact on its financial or operational activities.

The matter has been successfully resolved with the payment of the prescribed compounding fee, allowing the company to maintain its focus on regular business operations without any ongoing regulatory overhang from this specific packaging compliance issue.